Purchase this article with an account.
Catharina Busch, Matias Iglicki, Dinah Zur, Mali Okada, Jay Chhablani, Zafer Cebeci, Samantha Fraser-Bell, Voraporn Chaikitmongkol, Aude Couturier, Ermete Giancipoli, Patricio Rodriguez, Matus Rehak, Marco Lupidi, Adrian Tien-Chin Fung, Michaella Goldstein, Anat Loewenstein; Dexamethasone Implant for Diabetic Macular Edema in Naïve Compared To Refractory Eyes –A 24 Month The International Retina Group Real-Life Multicenter Study - IRGRel-DEX Study. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1956. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate efficacy and safety of repeated dexamethasone (DEX) implants over 24 months in a real-life environment, in diabetic macular edema (DME) eyes that were treatment-naïve compared to eyes refractory to anti-VEGF treatment.
This multicenter international retrospective study assessed best corrected visual acuity (BCVA) and central subfield thickness (CST) of naïve and refractory eyes to anti-VEGF injections treated with DEX implants. Safety data (intraocular pressure rise and cataract surgery) were recorded.
130 eyes from 125 patients were included. Baseline BCVA and CST were similar for naïve and refractory eyes. Both groups improved significantly in vision after 24 months (p< 0.001). However, naïve eyes gained statistically significant more vision than refractory eyes (BCVA 0.36 ± 0.14 versus 0.47 ± 0.23 logMAR, p=0.005) and were more likely to gain ≥ 10 letters (OR 4.2, 95% CI 1.38 - 12.90, p=0.01). At 6, 12 and 24 months, CST was significantly decreased compared to baseline in both naïve and refractory eyes; however, CST was increased in refractory compared to naïve eyes (CST 279 ± 61 versus 313 ± 125, p=0.06).
Over a follow up of 24 months, vision improved in DME eyes following treatment with DEX implants, both in eyes that were treatment-naïve and eyes refractory to anti-VEGF treatment; however, improvement was greater in naïve eyes.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only